TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00769379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Breast Irradiation
Description: Undergo standard whole breast irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Breast Irradiation
Description: Undergo standard whole breast irradiation
Study: NCT04439331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib Hydrochloride
Description: Given PO
Study: NCT03388606

Intervention type: BEHAVIORAL
Intervention: Growth Mindset
Description: 30 Minute interactive video
Study: NCT01585246

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: soybean oil soft gel
Description: placebo (soybean oil soft gel)
Study: NCT04552132

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multisonic vs Sonic activation of irrigants
Description: Energy is input into the intracanal irrigants for activation in the hopes of increasing irrigant efficacy.
Study: NCT00750841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib
Description: 45 mg cediranib once daily from Days 1-7; cediranib 45 mg plus 600 mg rifampicin from Days 8-14; 45 mg cediranib once daily from Days 15-28; from Day 29 patients may continue on 45 mg cediranib or dose reduce.
Study: NCT04363697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT02240238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC-6004
Description: NC-6004 - given at escalating doses of 60, 75, 90, 105, 120, 135, 150, 165, or 180 mg/m2 according to observations of dose-limiting toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250 mg/m2 will be administered as a 30 minute intravenous infusion on Day 1 after the completion of the NC 6004 infusion and on Day 8 of each cycle.
Study: NCT03819465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danvatirsen
Description: Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danvatirsen
Description: Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
Study: NCT04552132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multisonic vs Sonic activation of irrigants
Description: Energy is input into the intracanal irrigants for activation in the hopes of increasing irrigant efficacy.
Study: NCT00920959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP 100mcg
Description: Once-daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSC 100/50mcg
Description: Once-daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once-daily dosing
Study: NCT02600923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
Study: NCT03540732

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indirect Calorimetry directed feeding.
Description: Indirect calorimetry directed feeding (use of indirect calorimetry to calculate daily caloric requirement)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cycle Ergometry
Description: Up to 60 minutes of cycle ergometry daily in addition to standard physiotherapy sessions.
Study: NCT02931786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol, midazolam and atropine administration via intravenous cannula.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol, midazolam and atropine administration via intravenous cannula.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine propofol mixture
Description: Administration of ketamine propofol mixture, midazolam and atropine via intravenous cannula

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine propofol mixture
Description: Administration of ketamine propofol mixture, midazolam and atropine via intravenous cannula
Study: NCT04262063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tell play do technique
Description: it apply the concept of learning by doing .children will enjoy playing with customized dental models

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: tell show do
Description: Tell: your dentist explaining to you what they'd like to do Show: showing you what is involved (e. g. showing the equipment and demonstrating it on a finger) Do: performing the procedure
Study: NCT01843803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient inventory
Description: Patients in the intervention arm will complete an inventory of their preferences, resources, and life circumstances that may affect their care. The inventory will be completed on an iPad, and a copy of the results will be given to the patient's provider at the time of their visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: attention control
Description: Patients will view a brief healthy living video on an iPad
Study: NCT03758157

Intervention type: DIAGNOSTIC_TEST
Intervention: welloStationX
Description: welloStationX is an automated electronic thermometer using an infrared sensor of the surface of the forehead to measure human body skin temperature to screen for fever.

Intervention type: DIAGNOSTIC_TEST
Intervention: SureTemp
Description: SureTemp is an oral thermometer to measure human body skin temperature.
Study: NCT00086450

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Graft
Description: For CABG, participants will receive general anesthesia and will have a breathing tube placed in their throat and they will be unconscious during the operation. An incision is made through the chest bone and muscle, which allows the surgeon access to the heart and diseased vessels. The surgeon will use one or more healthy vessels (either from an artery in the shoulder or a vein in the leg) and will bypass the diseased vessel with the healthy vessel(s). This bypass will provide needed blood supply to the heart.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: For PCI, the participant will have two or more drug-eluting stents permanently implanted in their clogged arteries. Drug-eluting stents are coated with a drug that may prevent the disease in the vessel from coming back. The brand names of the stents used in this study are TAXUS and CYPHER.~The participant will receive a local anesthetic. A small puncture will be made and a balloon-tipped catheter is introduced through the small puncture in the leg/arm and advanced through the artery to the diseased heart vessel. The balloon is then inflated to enlarge the opening in the vessel. After enlarging the vessel, the drug-eluting stent will be placed using a similar balloon catheter. This balloon will be inflated, expanding the stent and placing it in the diseased vessel. Once the stent is fully expanded, the balloon is deflated and removed, leaving the stent in place in the artery.
Study: NCT00614172

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation therapy
Description: Proton radiotherapy will start 2-4 weeks following surgical excision. The treatment area will include the lumpectomy site with an additional margin. Daily proton therapy will be given as an out-patient over a two week coarse.
Study: NCT03140163

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ULD-CT
Description: Siemens Healthcare SOMATOM FORCE Ultra Low Dose chest CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CXR
Description: Conventional chest radiograph
Study: NCT02633943

Intervention type: OTHER
Intervention: Safety and efficacy assessments
Description: Genetic: No interventional drug product utilized in this follow-up study~Participants received a single IV infusion of LentiGlobin BB305 Drug Product in the parent studies. Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term effects of autologous transplant are conducted in this study.
Study: NCT04058028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozibafusp Alfa
Description: Rozibafusp Alfa will be presented in 5 mL glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozibafusp Alfa
Description: Rozibafusp Alfa will be presented in 5 mL glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozibafusp Alfa
Description: Rozibafusp Alfa will be presented in 5 mL glass vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Rozibafusp Alfa
Description: Placebo for Rozibafusp Alfa will be presented in 5 mL glass vial
Study: NCT03751475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Strategy - OptiMA
Description: All children with a MUAC\<125mm or oedema will be treated with the same RUTF, according to a new dosage table based on the evolution of MUAC and weight during recovery (RUTF dosage prescribed is gradually reduced as weight and MUAC increase).~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet discharge criteria, and then a bimonthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effective nutritional standard strategy
Description: Children presenting with MUAC\<115 or WHZ\<-3 or nutritional oedema, will be treated with RUTF, according to the usual dosage table based on weight at each visit.~All children (whether eligible for RUTF or not) will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated). Children not eligible for RUTF at randomization will benefit from this same monthly community-based follow-up.
Study: NCT02108977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videoconferencing Genetic Consultation
Description: Patients will travel to CBOC and receive genetic counseling session via videoconferencing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teleconferencing Genetic Consultation
Description: Patients will receive genetic counseling session via telephone (usual treatment)
Study: NCT03749057

Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban
Description: Rivaroxaban 15-20 mg daily
Study: NCT04391842

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Device with 1% Diclofenac patch
Description: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 with 1% diclofenac patch~Other Names:~* ZetrOZ ultrasound device~* wearable ultrasound device~* long duration ultrasound~* LITUS device~* long duration low intensity device
Study: NCT00848029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent inactivated influenza vaccine
Description: Two doses of monovalent inactivated influenza adjuvanted vaccine
Study: NCT00223002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: sample collected at time of procedure and then analysed for bacterial contamination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: sample collected at time of procedure and then analysed for bacterial contamination
Study: NCT01566422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin powder
Description: patients randomized to this group will receive vancomycin powder in the surgical incision after posterior spinal fusion.
Study: NCT01363284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: First week of placebo. then, initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks
Study: NCT03314883

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: D-US ARF
Description: Diaphragm ultrasound evaluation in acute hypoxic - hypercapnic respiratory failure (ARF) patients undergoing non invasive ventilation, with regard to thickening (%) and excursion (millimeters)
Study: NCT04690634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic sleeve gastrectomy (LSG)
Description: Multiple studies have indicated that laparoscopic sleeve gastrectomy (LSG) was superior to nonsurgical approaches for the treatment of obese PCOS patients over both the short and long term

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy (LSG)
Description: Multiple studies have indicated that laparoscopic sleeve gastrectomy (LSG) was superior to nonsurgical approaches for the treatment of obese PCOS patients over both the short and long term
Study: NCT02938338

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Bariatric surgery, with an anticipated mean weight loss of 30 kg
Study: NCT03635762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be In Charge
Description: comparison of pre and post-program weight and calorie intake
Study: NCT02132143

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation
Description: For concurrent chemoradiotherapy, the intensity-modulated radiation therapy(IMRT)will be given at the first day of therapy,total dose of 5000cGy～6000cGy/5-6 Weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation
Description: For sequential chemoradiotherapy,the intensity-modulated radiation will(IMRT) will be given when patients received adjuvant chemotherapy for four cycles,total dose of 5000cGy～6000cGy/5-6 Weeks.
Study: NCT01204086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: The initial dose of venlafaxine was 37.5 mg once daily for 4 days titrated to 75 mg once daily, which could be increased by 75 mg in divided doses to a maximal daily dose of 225 mg.
Study: NCT04505436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15211
Description: A sterile solution of HM15211 (efocipegtrutide) contained in pre-filled syringes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of HM15211
Description: A sterile, matching solution in pre-filled syringes
Study: NCT01204086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 80 mg.
Study: NCT01818973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning, 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: iv, 130mg/m2, day 1, 1 cycle during neoadjuvant chemotherapy and 3 cycles in adjuvant chemotherapy 100mg/m2, day 1, 2 cycles during concurrent chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: iv, 7.5 mg/kg, day 1, 3 cycles during neoadjuvant chemotherapy and concurrent chemoradiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Intensity-modulated radiation therapy, 50 Gy/25 fractions during 5 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Total Mesorectal Excision (TME)
Study: NCT04967105

Intervention type: DEVICE
Intervention: Near-infrared spectroscopy
Description: Before the induction of anesthesia, NIRS sensors were placed on both sides of the flank area that overlies the kidney to monitor renal SO2, whose alteration trends over time during operation will be recorded and evaluated in later analysis.
Study: NCT00594230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat(20 mg or 30 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat(20 mg or 30 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator.
Study: NCT00179803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Group A: recurrent medulloblastoma, recurrent germ cell tumor~* Cytoxan treatment~* Stem cell autologous harvest~Group B: GBM, high grade astrocytoma, rhabdoid tumors, pineoblastoma, or supratentorial PNET~* Carboplatin and Etoposide treatment~* Autologous stem cell harvest~The preparatory regimen used for Stem Cell Rescue #1 will be Carboplatinum, VP-16 and Thiotepa. If the patient has recuperated his ANC to \>1,000 within 50 days after Stem Cell Rescue #1, (sustained without G-CSF support) a neuroradiographic evaluation will be performed. If there is lack of progression, the patient will then proceed to Stem Cell Rescue # 2 with Cyclophosphamide and Melphalan, followed by stem cell rescue.
Study: NCT04084730

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation
Description: Treatment will consist of APBI delivered using external beam RT techniques to a dose of 24 Gy in 3 fractions of 8.0 Gy delivered on consecutive weekdays
Study: NCT02045186

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of Oral HPV Infection
Description: Saliva and exfoliated oral epithelial cells will be collected with collection supplies provided by OralDNA Labs. Patients will swish and gargle a saline solution for 30 seconds and expectorate it into a funneled collection tube. The collected specimen will be sent to OralDNA Labs. Three diagnostic tests will be performed on each sample to assess oral HPV infection:~1. Polymerase chain reaction (PCR) for HPV DNA.~2. Fluorescent in-situ hybridization (FISH).~3. Viral expression: The test is based on the measurement of the viral RNA levels by methods of detection of the fluorochrome labeled HPV probes by flow cytometry.
Study: NCT05858866

Intervention type: OTHER
Intervention: Piper Fatigue Scale
Description: The Piper Fatigue Scale (PFS) was developed by Piper et al. to measure fatigue in a multi-dimensional manner. The scale assesses the behavioural, affective, sensory and cognitive/mood attributes of fatigue and contains 22 items and 5 open-ended questions. Each item is scored between 0 and 10 using a Visual Analogue Scale. Sub-scale scores are obtained by dividing the scores from the sub-scale items by the number of the items in the sub-scale. The same method is used to calculate the total score

Intervention type: OTHER
Intervention: Piper Fatigue Scale
Description: The Piper Fatigue Scale (PFS) was developed by Piper et al. to measure fatigue in a multi-dimensional manner. The scale assesses the behavioural, affective, sensory and cognitive/mood attributes of fatigue and contains 22 items and 5 open-ended questions. Each item is scored between 0 and 10 using a Visual Analogue Scale. Sub-scale scores are obtained by dividing the scores from the sub-scale items by the number of the items in the sub-scale. The same method is used to calculate the total score
Study: NCT04075461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Description: Arthroplasty is commonly used for a displaced femoral neck fracture.